Compare Adaptive Biotechnologies Corp (ADPT) vs Sea Limited (SE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sea Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Sea Limited trades at $103.87 (market cap $63.84B). The key difference: Sea Limited is far larger — about 19.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | SE | |
|---|---|---|
Market Cap | $3.33B | $63.84B |
Sector | Health | Media |
52-Week High | $22.37 | $196.50 |
52-Week Low | $10.24 | $78.16 |
Enterprise Value | $3.19B | $56.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sea Limited (SE) trades at $104.23, up 0.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarters have mixed earnings performance. Analyst consensus remains strongly positive with a $131 price target, supported by improving cash flow trends and expanding profitability.
The outlook for SE is favorable given robust growth in its digital ecosystem and positive analyst sentiment, but risks include competitive pressures in Southeast Asian markets and potential volatility from earnings misses. Investors should weigh the high P/E ratio of 41.34 against the company's accelerating top-line expansion and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
